ClinicalTrials.gg
Active, not recruitingNCT05883956PREFER-HMAUpdated Mar 20, 2025

A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia

A Phase 3 interventional study of Subcutaneous azacitidine and Oral decitabine/cedazuridine in Myelodysplastic Syndromes, Leukemia, Myeloid, Acute and Leukemia, Myelomonocytic, Chronic, sponsored by Otsuka Australia Pharmaceutical Pty Ltd. Active, not recruiting at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-20.

Sponsored by Otsuka Australia Pharmaceutical Pty Ltd (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 130 studies testing azacitidine in Myelodysplastic Syndromes — 13 open to participants now, 25 under way, 3 of them phase 3. Azacitidine · Myelodysplastic Syndromes.

Enrollment
101st of 126
13 · median 38
Started
2023
with 3 others
Phase 3
9 of 130
1 open now
Primary completion
2024-12
later than 3 of 24 live
Registered
120th of 130
by date

Among the 130 studies testing azacitidine in Myelodysplastic Syndromes, this one is the 101st largest by enrollment of the 126 interventional ones that give a count, is one of 4 that started in 2023, is one of 9 in phase 3, reaches primary completion later than 3 of the 24 other live ones, and was the 120th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

13 of the 130 studies testing azacitidine in Myelodysplastic Syndromes are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About azacitidine

Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing azacitidine in Myelodysplastic Syndromes, or all of them as a file.
02

Study summary

It is hypothesized that significantly more patients would prefer oral decitabine/cedazuridine to subcutaneous (SC) azacitidine (AZA) due to several factors, including improved treatment convenience, the reduced risk of nosocomial infections, and reduced treatment discomfort. However, this hypothesis has not been formally studied in a controlled setting. This study aims to address this evidence gap and evaluate patient, primary caregiver (carer), and clinician treatment preference between oral decitabine/cedazuridine and SC AZA in the treatment of adult patients with International Prognostic Scoring System-Revised (IPSS-R) intermediate, IPSS intermediate-2, or high-risk myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), or low-blast (LB) acute myeloid leukemia (AML) and thereby lend further credibility to the clinical, economic, and patient value of oral decitabine/cedazuridine.

03

Conditions studied

  • Myelodysplastic Syndromes
  • Leukemia, Myeloid, Acute
  • Leukemia, Myelomonocytic, Chronic
  • Patient Preference
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

For Patients:

Patients are eligible to be included in the study only if all of the following criteria apply at any time starting from Screening up to Day 1 prior to study treatment administration:

  • Patients must be 18 years of age or older.
  • IPSS-R defined intermediate MDS, IPSS defined intermediate 2 or high-risk MDS, LB AML or CMML (with symptoms), as confirmed by recent full blood examination, bone marrow , and cytogenetic testing. NOTE: IPSS-R defined intermediate MDS patients are limited to less than 50% of enrolled patients.
  • of at least 6 months.
  • (ECOG) Performance Status of 0 to 2 inclusive.
  • Patient must be able to co-operate and complete tasks (including tasks such as electronic questionnaires on digital devices) over the following 4 months.

Inclusion Criteria:

For Patients:

Patients are eligible to be included in the study only if all of the following criteria apply at any time starting from Screening up to Day 1 prior to study treatment administration:

  • Patients must be 18 years of age or older.
  • IPSS-R defined intermediate MDS, IPSS defined intermediate 2 or high-risk MDS, LB AML or CMML (with symptoms), as confirmed by recent full blood examination, bone marrow biopsy, and cytogenetic testing. NOTE: IPSS-R defined intermediate MDS patients are limited to less than 50% of enrolled patients.
  • Life expectancy of at least 6 months.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2 inclusive.
  • Patient must be able to co-operate and complete tasks (including tasks such as electronic questionnaires on digital devices) over the following 4 months.
  • Patient must be able to identify a carer to participate in completing the cTPMQ.

For Carers:

  • Primary carer of a patient meeting all of the inclusion criteria (ie, a patient who meets criteria defined above).

For Clinicians:

  • Clinician treating patients meeting all of the inclusion criteria (ie, treats patients who meet criteria defined above).

Exclusion Criteria:

For Patients:

Patients are excluded from the study if any of the following criteria apply:

  • Patients with known to the study treatments oral decitabine/cedazuridine or azacitidine.
  • Patients with advanced malignant hepatic tumors.
  • Patients with severe renal impairment ( \<30 mL/min).
  • Patients who have received hypomethylating agents (HMA) previously.
  • Patients who are receiving lenalidomide or are receiving other therapies outside of standard of care (SOC).
  • Receipt of any immunotherapy, any conventional or systemic anti-cancer therapy within 5 half-lives of the drug, or within 4 weeks prior to the first dose of study treatment (whichever is longer).
  • Any medical, psychological, social, or other condition which in the view of the Investigator is likely to interfere with the study, compliance, or put the patient at risk.
  • Participants who are not fluent in English, or who cannot read or write in English will be excluded from the study.

For Carers:

Carers are excluded from the study if any of the following criteria apply:

  • They are a carer of a patient who meets any of the exclusion criteria listed above.
  • They are a relative of an employee of the investigational clinic or sponsor (e.g. Investigator, study coordinator)

For Clinicians:

  • Clinicians will be excluded from participating in the study if they are a relative of an employee of the investigational clinic or sponsor (e.g. Investigator, Study Coordinator).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Active comparator
    ABBA

    Cycle 1: Oral decitabine/cedazuridine; Cycle 2: Subcutaneous azacitidine; Cycle 3: Subcutaneous azacitidine; Cycle 4: Oral decitabine/cedazuridine

    Drug: Subcutaneous azacitidine · Drug: Oral decitabine/cedazuridine

  • Active comparator
    BAAB

    Cycle 1: Subcutaneous azacitidine; Cycle 2: Oral decitabine/cedazuridine; Cycle 3: Oral decitabine/cedazuridine; Cycle 4: Subcutaneous azacitidine

    Drug: Subcutaneous azacitidine · Drug: Oral decitabine/cedazuridine

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of patients reporting preference for oral decitabine/cedazuridine vs subcutaneous azacitidine on the patient treatment preference in myelodysplasia questionnaire (pTPMQ)

    Time frame: Prior to initiation of Cycle 3 (each cycle is 28 days)

  2. Proportion of patients reporting preference for oral decitabine/cedazuridine vs subcutaneous azacitidine on the pTPMQ

    Time frame: Prior to initiation of Cycle 5 (each cycle is 28 days)

Secondary outcomes

  1. Proportion of carers reporting preference for oral decitabine/cedazuridine vs subcutaneous azacitidine on the carer treatment preference in myelodysplasia questionnaire (cTPMQ)

    Time frame: Prior to initiation of Cycle 3 (each cycle is 28 days)

  2. Proportion of carers reporting preference for oral decitabine/cedazuridine vs subcutaneous azacitidine on the cTPMQ

    Time frame: Prior to initiation of Cycle 5 (each cycle is 28 days)

  3. Proportion of clinicians reporting preference for oral decitabine/cedazuridine vs subcutaneous azacitidine on the medical treatment preference in myelodysplasia questionnaire (mTPMQ)

    Time frame: Prior to initiation of Cycle 4 (each cycle is 28 days)

  4. Proportion of clinicians reporting preference for oral decitabine/cedazuridine vs subcutaneous azacitidine on the mTPMQ

    Time frame: End of Study (EOS) Day 28

  5. Proportion of clinicians choosing oral decitabine/cedazuridine vs subcutaneous azacitidine for continuation of treatment and reasons for the treatment choice based on the mTPMQ

    Time frame: Cycle 5, Day 1 (each cycle is 28 days)

  6. Difference in quality of life between oral decitabine/cedazuridine and subcutaneous azacitidine as assessed using the EQ-5D-5L in Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myeloid Leukemia patients

    Time frame: Cycle 1, Day 1 (each cycle is 28 days)

  7. Difference in quality of life between oral decitabine/cedazuridine and subcutaneous azacitidine as assessed using the EORTC QLQ-C30 in Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myeloid Leukemia patients

    Time frame: Cycle 1, Day 1 (each cycle is 28 days)

  8. Difference in quality of life between oral decitabine/cedazuridine and subcutaneous azacitidine as assessed using the EQ-5D-5L in Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myeloid Leukemia patients

    Time frame: Cycle 3, Day 5 (each cycle is 28 days)

  9. Difference in quality of life between oral decitabine/cedazuridine and subcutaneous azacitidine as assessed using the EORTC QLQ-C30 in Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myeloid Leukemia patients

    Time frame: Cycle 3, Day 5 (each cycle is 28 days)

  10. Difference in quality of life between oral decitabine/cedazuridine and Subcutaneous azacitidine as assessed using the EQ-5D-5L in Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myeloid Leukemia patients

    Time frame: Cycle 4, Day 5 (each cycle is 28 days)

  11. Difference in quality of life between oral decitabine/cedazuridine and Subcutaneous azacitidine as assessed using the EORTC QLQ-C30 in Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myeloid Leukemia patients

    Time frame: Cycle 4, Day 5 (each cycle is 28 days)

  12. Difference in quality of life between oral decitabine/cedazuridine and subcutaneous azacitidine as assessed using the EQ-5D-5L in Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myeloid Leukemia patients

    Time frame: Cycle 5, Day 5 (each cycle is 28 days)

  13. Difference in quality of life between oral decitabine/cedazuridine and subcutaneous azacitidine as assessed using the EORTC QLQ-C30 in Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myeloid Leukemia patients

    Time frame: Cycle 5, Day 5 (each cycle is 28 days)

  14. Difference in quality of life between oral decitabine/cedazuridine and subcutaneous azacitidine as assessed using the EQ-5D-5L in Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myeloid Leukemia patients

    Time frame: Cycle 6, Day 5 (each cycle is 28 days)

  15. Difference in quality of life between oral decitabine/cedazuridine and subcutaneous azacitidine as assessed using the EORTC QLQ-C30 in Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myeloid Leukemia patients

    Time frame: Cycle 6, Day 5 (each cycle is 28 days)

  16. The difference in the incidence of treatment discontinuation and reasons for treatment discontinuation

    Time frame: Baseline (pre-intervention) through to study completion (up to 6 cycles of treatment where each cycle is 28 days)

  17. Incidence and severity of adverse events upon study physician discretion.

    Time frame: Baseline (pre-intervention) through to study completion (up to 6 cycles of treatment where each cycle is 28 days)

07

Study locations

11 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in Dec 2024, 11 months.

Of 26 industry-sponsored phase 3 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 52. This study's 11 months is below that.

Counting every sponsor, half of 45 studies reached it within 50 months; a quarter within 38 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2023
First posted
Jun 1, 2023
StartActual
Dec 20, 2023
Primary completionActual
Dec 6, 2024
CompletionEst.
May 2025
Last update
Mar 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05883956
Responsible party
Sponsor
First posted
Jun 1, 2023
Start date
Dec 20, 2023
Primary completion
Dec 6, 2024
Completion
May 2025 (estimated)
Last update
Mar 20, 2025

Study contacts

Anoop Enjeti
principal investigator · Calvary Mater Newcastle, Edith Street, Waratah, NSW 2298 Australia

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Azacitidine · Decitabine · Cedazuridine

Start the discussion